CHIRALDEX B-DA requires that analytes possess a minimum of two ring structures, one of which is unsaturated (aromatic) α, β to the stereogenic center. Examples include fluoxetine, methylphenidate and chloropheniramine. Inclusion complexation or proper fit between the analyte and cyclodextrin cavity is the dominant enantioselectivity mechanism for the DA series. There must be an includable group α or β to the stereogenic center for chiral recognition. Since CHIRALDEX DA columns most effectively separate multi-ring analytes, analysis temperatures are often higher than 150°C. Enantioselectivity has been observed at temperatures >200°C (fluoxetine acetyl derivative).

Applications:
Agriculture,chemicals and industrial polymers, cleaning products, clinical, cosmetics, environmental, flavors and fragrances, food and beverages, forensics and toxicology, life science and biopharma, personal care, pharmaceutical (small molecule)

Matrix Active Group:
non-bonded; 2,6-di-O-pentyl-3-methoxy derivative of β-cyclodextrin phase

Temp Limits:
-10-200 °C temperature (isothermal)
-10-220 °C temperature (programmed)